AU2007231651B2 - Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors - Google Patents
Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors Download PDFInfo
- Publication number
- AU2007231651B2 AU2007231651B2 AU2007231651A AU2007231651A AU2007231651B2 AU 2007231651 B2 AU2007231651 B2 AU 2007231651B2 AU 2007231651 A AU2007231651 A AU 2007231651A AU 2007231651 A AU2007231651 A AU 2007231651A AU 2007231651 B2 AU2007231651 B2 AU 2007231651B2
- Authority
- AU
- Australia
- Prior art keywords
- defibrotide
- angiogenesis
- use according
- formulation
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 30
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 229960004120 defibrotide Drugs 0.000 title claims abstract description 29
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 26
- 230000001419 dependent effect Effects 0.000 title claims abstract description 13
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 title abstract description 5
- 238000000605 extraction Methods 0.000 claims abstract description 8
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 5
- 241001465754 Metazoa Species 0.000 claims abstract description 5
- 235000013311 vegetables Nutrition 0.000 claims abstract description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 4
- 201000008275 breast carcinoma Diseases 0.000 claims abstract description 4
- 210000000056 organ Anatomy 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 12
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 6
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 6
- 229960002930 sirolimus Drugs 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000009471 action Effects 0.000 abstract description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 description 11
- 238000003556 assay Methods 0.000 description 8
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000005166 vasculature Anatomy 0.000 description 4
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 3
- 210000002358 circulating endothelial cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- -1 alkali-metal salt Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000009764 endothelial cell sprouting Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Abstract The use of defibrotide and/or oligodeoxyribonucleotides having a molecular weight of 4000-10000 Dalton as an 5 anti-tumour agent, alone or in combination with other active ingredients with anti-tumour action, is described. The oligotide may be produced by extraction from animal and/or vegetable tissues, in particular, from mammalian organs, or may be produced 10 synthetically. The tumours which can be treated are preferably angiogenesis-dependent tumours, such as multiple myeloma or breast carcinoma. Oliotdi W~ Dnthibit--s. tube- forMati f of ELC,, HMMCd7 C--* HME -, dlD.F [1Op L-1 H VE d7 ;w/o0 H'uv+E~cd7 + D iOg/L
Description
AUSTRALIA Patents Act 1990 COMPLETE SPECIFICATION Standard Patent Applicant: Gentium SPA Invention Title: DEFIBROTIDE AND/OR OLIGODEOXYRIBONUCLEOTIDES FOR TREATING ANGIOGENESIS-DEPENDENT TUMORS The following statement is a full description of this invention, including the best method for performing it known to me/us: la Formulations with anti-angiogenesis-dependent tumour action The subject of the present invention is a method for treating a tumor-affected mammalian by administering to said mammalian an effective amount of defibrotide and/or oligotide; in particular it relates to the use of oligotide and/or defibrotide for the treatment of angiogenesis-dependent tumors. Background of the invention Angiogenesis is a multi-step process leading to the formation of new blood vessels from pre-existing vasculature and it is necessary for primary tumor growth, invasiveness and development of metastases (20) . It is normally suppressed in the adult, where angiogenesis occurs transiently only during reproduction, development and wound healing. Beyond a critical volume, a tumor cannot expand further in the absence of neovascularization (12) . To promote this, a tumor must acquire the angiogenic phenotype which is the result of the net balance between positive (pro angiogenic) and negative (anti-angiogenic) regulators (16). However, tumors are highly heterogenous in vascular architecture, differentiation, and functional blood supply (24). These differences in size of avascular preangiogenic tumors may be due in part to the capacity of tumor cells to survive under differing degrees of hypoxia (18). Evidence for the angiogenesis-dependency of certain tumors, such as multiple myeloma, even non-solid leukemias and lymphomas (8) and (21), as well as breast (25), colorectal (7), gastric (26), prostate (9), cervix (19), hepatocellular (23), and non-small cell lung cancer (13) came from the observation that the 2 measure of the degree of angiogenesis, the microvessel density, is an independent prognostic factor for survival in the mentioned clinical entities (17). In a recent clinical study, again in breast carcinoma, it became clear that angiogenesis-related genes are important for clinical outcome, for example the vascular endothelial cell growth factor VEGF, the VEGF receptor FLT1, and metalloproteinase MMP9 (6). Definitions The term oligotide is herein used to identify any oligodeoxyribonucleotide having a molecular weight of 4000-10000 Dalton. Preferably it identifies any oligodeoxyribonucleotide having the following analytical parameters: molecular weight (mw) : 4000-10000 Dalton, hyperchromicity (h): <10, A+T/C+G: 1.100-1.455, A+G/C+T: 0.800-1.160, specific rotation: +30"- +46.80, preferably +30" +46.20. The oligotide may be produced by extraction from animal and/or vegetable tissues, in particular, from mammalian organs, or may be produced synthetically. Preferably, when produced by extraction, it will be obtained in accordance with the method described in (1), (2), and (3) which are incorporated herein by reference. The oligotide is known to be endowed with a significant anti-ischemic activity. The term defibrotide identifies a polydeoxyribonucleotide that is obtained by extraction from animal and/or vegetable tissues but which may also 3 be produced synthetically; the polydesoxyribo-nucleotide is normally used in the form of an alkali-metal salt, generally a sodium salt, and generally has a molecular weight of about 45-50 kDa (CAS Registry Number: 83712-60 5 1). Preferably, defibrotide presents the physical/chemical characteristics described in (4) and (5), which are incorporated herein by reference. DESCRIPTION OF THE INVENTION 10 The present invention provides the following items (1) to (12): (1) Use of defibrotide in combination with rapamycin for the manufacture of a pharmaceutical 15 formulation for the treatment of angiogenesis dependent tumour. (2) A method for the treatment of angiogenesis dependent tumour, comprising administering a pharmaceutical formulation comprising 20 defibrotide in combination with rapamycin. (3) Use according to item (1), or a method according to item (2), characterized in that said defibrotide is obtained by extraction from animal and/or vegetable tissues. 25 (4) Use according to item (1), or a method according to item (3), characterized in that said defibrotide is obtained by extraction from mammalian organs. (5) Use according to item (1) or a method according 30 to item (2), characterized in that said defibrotide is obtained synthetically. 565409.1 (GHMatters) 3a (6) Use according to item (1), or a method according to item (2), characterized in that said angiogenesis-dependent tumor is multiple myeloma. 5 (7) Use according to item (1), or a method according to item (2), characterized in that said angiogenesis-dependent tumour is breast carcinoma. (8) Use according to item (1), or a method 10 according to item (2), characterized in that said formulation is administered to a mammalian. (9) Use according to item (1), or a method according to item (2), characterized in that 15 said formulation is administered to a human. (10) Use according to item (1), or a method according to item (2), characterized in that said formulation is administered intravenously. (11) Use according to item (1), or a method 20 according to item (2), characterized in that said formulation is an aqueous solution. (12) Use according to item (1), or a method according to item (2), characterized in that said formulation contains customary excipients 25 and/or adjuvants. 565409_1 (GHMatters) 3b We have recently developed a model for an alternative pathway of tumor angiogenesis. In addition to the endothelial cell sprouting from pre-existing vessels, we suggest that blood borne endothelial cells might also give rise to the tumor vasculature. These endothelial-like cells (ELC) can transdifferentiate from tumor-associated dendritic cells under specific culture conditions (11) . Briefly, monocytes are elutriated from leukapheresis products of healthy human blood donors and cultured in the presence of granulocyte-macrophage-colony stimulating factor (GM CSF) and interleukin 4 (IL-4) to stimulate the differentiation of dendritic cells (DC). In addition, cells are treated with a cocktail specifically released by tumor cells (M-CSF, IL.6 and lactate, Gottfried et al., manucript submitted) to promote the outgrowth of tumor-associated dendritic cells (TuDC). These TuDC-ELC acquire the phenotype of endothelial cells (FactorVIII related Ag, vWF) while they lose monocytic (CD14) and dendritic cell markers (CDla). Importantly, they do not express CD34, nor CD133 or CD146 which proves that they are real transdifferentiation products and no contaminants of either circulating endothelial progenitors (CD34, CD133) or mature circulating endothelial cells (CD146).
4 In addition, they are able to form tube-like structures in MatrigelTM, an in vitro assay of angiogenesis. The MatrigelTM assay is one of the most popular and widely used in vitro angiogenesis assays (22). MatrigelTM is a semisolid synthetic mixture of extracellular matrix proteins which simulate the matrix that physiologically exist beneath the endothelial cell wall of a blood vessel. When the cells of question are seeded onto this matrix in microscopic chamber slides, they are activated to form tubular structures in 3-7 days, but only in the case that they have an endothelial phenotype. Therefore, this assay is suitable to show the potential capacity of cells to give rise to a tumor vasculature. Our data data demonstrate that oligotide and/or defibrotide in clinical and subclinical concentrations can inhibit tube formation of transdifferentiating ELC (TuDC-ELC) in MatrigelTM. TuDC-ELC and mature, differentiated endothelial cells, [human umbilical vene (HUVEC) or microvascular endothelial cells (HMEC) as "stable" controls] were incubated in the presence or absence of oligotide or Defibrotide (10pg/mL each) for 7 days. Importantly, after a single addition of Defibrotide, HUVEC and HMEC are not affected in their tube formation potential, suggesting that Defibrotide and/or oligotide only target transdifferentiating endothelial cells (Figure 1 A) . However, when Defibrotide was added repeatedly, it could also block angiogenesis of mature, fully differentiated endothelial cells (see below). By the help of a complimentary software from the NIH (Image J, http://rsb.info.nih.gov/ij/), we are able to quantify these effects, the total length of tubes and 5 the area of the photograph are assessed, the microvascular density (MVD) is then given in total length/area [pix-1]. DF significantly (p=0.02, TTEST) downregulates MVD of TuDC-ELC (Figure 1 B). To support these data with an alternative angiogenesis assay the sprouting of rat aorta endothelial cells in MatrigelTM was prevented by nearly 100%, when DF was applied on a daily basis (Figure 2), suggesting that DF not only acts on transdifferentiating, but also on mature, fully differentiated endothelial cells. The aortic ring assay investigates macrovascular endothelial cells. But often, the tumor vasculature consists of microvascular endothelial cells. Therefore, a third in vitro angiogenesis assay was performed on the basis of microvascular endothelial cells vascularizing through a layer of dermal fibroblasts after 9-11 days of culture. These vessel-like structures can subsequently be visualized by staining for CD31 and vWF. As demonstrated in Figure 3 (A and B), DF can also block angiogenesis of human microvascular endothelial cells with a superiority for the daily application. Interestingly, concentrations around 10 pg/mL appear to be the most effective. A single application of DF could not significantly block angiogenesis. Taken together, our data strongly suggest that defibrotide and/or oligotide can block angiogenesis of tumor-associated transdifferentiating endothelial cells and those that arise from already existing vascular cells. It is subject to ongoing studies whether oligotide and defibrotide also inhibit angiogenesis in vivo. We are currently performing a dorsal skin chamber assay (14) 6 that investigates the effect of defibrotide in a highly vascularized human gastric carcinoma mouse model (Xenograft system) . First data clearly show that the microvascular density (MVD) of DF-treated tumors is lower than that of control tumors. This set of experiments will be reproduced in due time. The mechanism of action by which DF can block angiogenesis remains to be elucidated, but preliminary evidence from Western Blot analyses suggest a downregulating effect of DF on activated p70S6 kinase (p-p70S6), a mitogen-activated protein kinase. Additional evidence for the impact of p70S6 kinase was obtained from another tube formation assay with HMEC incubated in the presence or absence of the p70S6 kinase inhibtor DRB. There are also first clinical data available for patients (pts.) having received allogeneic stem cell transplantation (SCT): In a cohort of 17 defibrotide treated pts a striking decline in serum VEGF levels has been seen, also suggesting that defibrotide might act through growth factor withdrawal for sprouting tumor endothelial cells. Defibrotide and oligotide are strong candidates for a therapy of angiogenesis-dependent tumors and might be used alone or in combination with other anti angiogeneic agents, such as rapamycin (14). Interestingly, rapamycin has the negative side effect of pro-thrombotic activity (15) that could be attenuated by the simultaneous application of the anti thrombotic and fibrionolytic defibrotide. References 1. US5646127 7 2. US5646268 3. US6046172 4. US4985552 5. US5223609 6. 't Veer,L.J., et al.(2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530-536. 7. Abdalla,S.A., et al. (1999) Prognostic relevance of microvessel density in colorectal tumours. Oncol.Rep., 6, 839-842. 8. Andersen,N.F., et al. (2005) Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br.J.Haematol., 128, 210-217. 9. Bostwick,D.G. & Iczkowski,K.A. (1998) Microvessel density in prostate cancer: prognostic and therapeutic utility. Semin.Urol.Oncol., 16, 118 123. 10. Eissner,G., et al. (2002) Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood, 100, 334-340. 11. Fernandez,P.B., et al. (2001) Dendritic cells derived from peripheral monocytes express endothelial markers and in the presence of angiogenic growth factors differentiate into endothelial-like cells. Eur.J.Cell Biol., 80, 99 110. 12. Folkman,J., et al. (1971) Isolation of a tumor factor responsible for angiogenesis. J.Exp.Med., 133, 275-288.
8 13. Fontanini,G., et al. (1995) Microvessel count predicts metastatic disease and survival in non small cell lung cancer. J.Pathol., 177, 57-63. 14. Guba,M., et al. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat.Med., 8, 128-135. 15. Guba,M., et al. (2005) Rapamycin induces tumor specific thrombosis via tissue factor in the presence of VEGF. Blood. 16. Hanahan,D. & Folkman,J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353-364. 17. Hasan,J., et al. (2002) Intra-tumoural microvessel density in human solid tumours. Br.J.Cancer, 86, 1566-1577. 18. Helmlinger,G., et al. (1997) Interstitial pH and p02 gradients in solid tumors in vivo: high resolution measurements reveal a lack of correlation. Nat.Med., 3, 177-182. 19. Kainz,C., et al. (1995) Prognostic value of tumour microvessel density in cancer of the uterine cervix stage IB to IIB. Anticancer Res., 15, 1549-1551. 20. Morabito,A., et al. (2004) Antiangiogenic strategies, compounds, and early clinical results in breast cancer. Crit Rev.Oncol.Hematol., 49, 91 107. 21. Podar,K. & Anderson,K.C. (2005) The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood, 105, 1383-1395.
9 22. Staton,C.A., et al. (2004) Current methods for assaying angiogenesis in vitro and in vivo. Int.J.Exp.Pathol., 85, 233-248. 23. Sun,H.C., et al. (1999) Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J.Cancer Res.Clin.Oncol., 125, 419-426. 24. Verheul,H.M., et al. (2004) Are tumours angiogenesis-dependent? J.Pathol., 202, 5-13. 25. Weidner,N., et al. (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J.Natl.Cancer Inst., 84, 1875-1887. 26. Xiangming,C., et al. (1998) Angiogenesis as an unfavorable factor related to lymph node metastasis in early gastric cancer. Ann.Surg.oncol., 5, 585 589. It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country. In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.
Claims (13)
1. Use of defibrotide in combination with rapamycin for the manufacture of a pharmaceutical formulation for the treatment 5 of angiogenesis-dependent tumour.
2. A method for the treatment of angiogenesis-dependent tumour, comprising administering a pharmaceutical formulation comprising defibrotide in combination with rapamycin.
3. Use according to claim 1, or a method according to 10 claim 2, characterized in that said defibrotide is obtained by extraction from animal and/or vegetable tissues.
4. Use according to claim 1, or a method according to claim 3, characterized in that said defibrotide is obtained by extraction from mammalian organs. 15
5. Use according to claim 1, or a method according to claim 2, characterized in that said defibrotide is obtained synthetically.
6. Use according to claim 1, or a method according to claim 2, characterized in that said angiogenesis-dependent 20 tumor is multiple myeloma.
7. Use according to claim 1, or a method according to claim 2, characterized in that said angiogenesis-dependent tumour is breast carcinoma.
8. Use according to claim 1, or a method according to 25 claim 2, characterized in that said formulation is administered to a mammalian.
9. Use according to claim 1, or a method according to claim 2, characterized in that said formulation is administered to a human. 585409_1 (GHMatters) III
10. Use according to claim 1, or a method according to claim 2, characterized in that said formulation is administered intravenously.
11. Use according to claim 1, or a method according to s claim 2, characterized in that said formulation is an aqueous solution.
12. Use according to claim 1, or a method according to claim 2, characterized in that said formulation contains customary excipients and/or adjuvants. 10
13. Use according to claim 1 or a method according to claim 2, substantially as herein described with reference to any one of the accompanying drawings. 1 5 6 565409_1 (GHMatters)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2007231651A AU2007231651B2 (en) | 2005-03-03 | 2007-10-25 | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2005A000336 | 2005-03-03 | ||
| US60/731,404 | 2005-10-28 | ||
| AU2006222044A AU2006222044A1 (en) | 2005-03-03 | 2006-02-27 | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
| AU2007231651A AU2007231651B2 (en) | 2005-03-03 | 2007-10-25 | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006222044A Division AU2006222044A1 (en) | 2005-03-03 | 2006-02-27 | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2007231651A1 AU2007231651A1 (en) | 2007-11-15 |
| AU2007231651B2 true AU2007231651B2 (en) | 2011-09-15 |
Family
ID=39410435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007231651A Ceased AU2007231651B2 (en) | 2005-03-03 | 2007-10-25 | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2007231651B2 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998048843A1 (en) * | 1997-04-28 | 1998-11-05 | Arsinur Burcoglu | Method of treating hiv infection and related secondary infections thereof |
| DE19740384A1 (en) * | 1997-09-08 | 1999-03-11 | Max Delbrueck Centrum | Antisense oligonucleotides specific for protein kinase C isoforms |
-
2007
- 2007-10-25 AU AU2007231651A patent/AU2007231651B2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998048843A1 (en) * | 1997-04-28 | 1998-11-05 | Arsinur Burcoglu | Method of treating hiv infection and related secondary infections thereof |
| DE19740384A1 (en) * | 1997-09-08 | 1999-03-11 | Max Delbrueck Centrum | Antisense oligonucleotides specific for protein kinase C isoforms |
Non-Patent Citations (1)
| Title |
|---|
| Mitsiades et al. Blood (2003) vol. 102, no. 11, page 693A * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007231651A1 (en) | 2007-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment | |
| JP6902570B2 (en) | Efficient in vivo protein expression using modified RNA (MOD-RNA) | |
| Liu et al. | A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes | |
| Yao et al. | Co-delivery of sorafenib and VEGF-siRNA via pH-sensitive liposomes for the synergistic treatment of hepatocellular carcinoma | |
| AU2006222045B2 (en) | Oligodeoxyribonucleotides of 4000-10000 Dalton for treating tumors | |
| Goodwin et al. | Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis | |
| Feng et al. | EGFL7 is an intercellular EGFR signal messenger that plays an oncogenic role in glioma | |
| Yan et al. | Decreasing CNPY2 expression diminishes colorectal tumor growth and development through activation of p53 pathway | |
| El-Tanani et al. | Impact of exosome therapy on pancreatic cancer and its progression | |
| Wufuer et al. | Downregulation of Rac1/PAK1/LIMK1/cofilin signaling pathway in colon cancer SW620 cells treated with Chlorin e6 photodynamic therapy | |
| Rajendran et al. | Engineered extracellular vesicle mimetics from macrophage promotes hair growth in mice and promotes human hair follicle growth | |
| Xie et al. | Jianpi Huayu decoction inhibits the epithelial–mesenchymal transition of hepatocellular carcinoma cells by suppressing exosomal miR-23a-3p/Smad signaling | |
| Zhu et al. | CXC motif chemokine receptor type 4 disrupts blood-brain barrier and promotes brain metastasis through activation of the PI3K/AKT pathway in lung cancer | |
| Liu et al. | G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice | |
| AU2007231651B2 (en) | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors | |
| Zhang et al. | Biomimetic immortalized mesenchymal stem cell-based nanoparticles suppress orthotopic postsurgical glioma via CD73 targeting and chemotherapy | |
| EP1867335B1 (en) | Oligodeoxyribonucleotides combined with rapamycin for treating cancer | |
| CN103705505A (en) | Novel application of simvastatin | |
| KR20050007455A (en) | Method to inhibit cell growth using oligonucleotides | |
| Wu et al. | Ergosta-7, 22-diene-2β, 3α, 9α-triol (EGDT) from Ganoderma lucidum inhibits nasopharyngeal carcinoma cells by blocking EGFR signaling pathway | |
| Chen et al. | Comparison of tumor-derived total RNA and cell lysate on antitumor immune activity | |
| Kang et al. | EGFL7 is an intercellular EGFR signal messenger that plays an oncogenic role in glioma | |
| Huang et al. | Flavonoids from Millettia Speciosa Champ Inhibit the Migration and Angiogenesis of Prostate Cancer Cells | |
| 이지은 | Inhibition of Energy Metabolism by Toxoplasma gondii GRA16 in Colorectal Cancer Cells | |
| Li et al. | PI3K inhibitor promotes tumor vessel normalization and improves treatment outcomes of breast cancer with doxorubicin. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |